- May 22
- 11 min read
TL;DR: Yescarta and Kymriah both target CD19 but treat different lymphoma/leukemia situations. Carvykti targets BCMA and treats multiple myeloma, not lymphoma. The right CAR T product depends on your diagnosis, prior treatments, and treatment center—not brand preference. US total costs often exceed $500,000, while China-based CAR T pathways may cost far less.
Your oncologist said three words—CAR T therapy—and now you have seventeen browser tabs open, three drug names you can barely pronounce, and no clear answer to the only question that matters:
which one is actually for you?
This guide cuts through the jargon. You will learn what Yescarta, Kymriah, and Carvykti actually treat, how they differ, what they cost, what side effects matter, and what options may exist if the US price tag is out of reach. No pharmaceutical marketing. No false hope. Just the comparison a patient or caregiver needs before the next oncology appointment.
Why These Three? And Why the Others Matter Too
There are multiple FDA-approved CAR T products in the US, including Yescarta, Kymriah, Carvykti, Tecartus, Breyanzi, and Abecma. These therapies all use the same basic idea: your T cells are collected, genetically modified, expanded, and returned to your body so they can recognize cancer cells more effectively. But the target protein determines which cancer they can treat. The FDA’s CAR T class safety notice lists the currently approved BCMA- and CD19-directed products, including the six major US products patients most often compare.
Yescarta and Kymriah target CD19, a marker found on many B-cell blood cancers such as diffuse large B-cell lymphoma, follicular lymphoma, and B-cell acute lymphoblastic leukemia. Carvykti targets BCMA, a marker used in multiple myeloma. That means the first decision is not “which brand sounds best?” It is “what cancer do I have, and does that cancer express the right target?”
Patient takeaway: CAR T is not one drug. It is a platform. If you have multiple myeloma, Yescarta and Kymriah are not for you. If you have lymphoma, Carvykti is not for you.
For a broader six-product overview, see: /fda-approved-car-t-cell-therapy-2026/
Yescarta: The Adult Lymphoma Standard
Yescarta is the brand name for axicabtagene ciloleucel, often shortened to axi-cel. It is FDA-approved for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months, for adults with relapsed/refractory large B-cell lymphoma after two or more lines of therapy, and for adults with relapsed/refractory follicular lymphoma after two or more lines. It is not a pediatric CAR T product and it is not used for multiple myeloma.
Yescarta is often discussed as a major adult DLBCL option because it has strong long-term data. In the ZUMA-1 5-year follow-up, the estimated 5-year overall survival was 42.6% in treated patients with refractory large B-cell lymphoma, and the authors concluded the data supported durable response and potential curative benefit in a subset of patients.
A key technical feature is Yescarta’s CD28 co-stimulatory domain. In plain English, that means the engineered T cells tend to expand quickly and act aggressively. That can be valuable in fast-moving lymphoma, where time matters. The trade-off is toxicity: CD28-based products are often associated with more early inflammatory and neurologic toxicity than 4-1BB-based products, although comparisons are imperfect because products differ in more than one way.
The practical reality is that Yescarta requires a certified, experienced treatment center. In the US, the full process usually includes consultation, insurance authorization, leukapheresis, manufacturing, bridging therapy when needed, lymphodepleting chemotherapy, infusion, and monitoring. The drug acquisition price is only one part of the bill; real-world total CAR T costs are often several hundred thousand dollars higher once hospitalization and complication management are included.
Kymriah: The Pediatric Pioneer and Adult Option
Kymriah is the brand name for tisagenlecleucel, or tisa-cel. It was the first CAR T therapy approved in the US and remains especially important because of its pediatric and young-adult leukemia indication. The FDA lists Kymriah for patients up to age 25 with refractory or second-or-later relapsed B-cell precursor ALL, adults with relapsed/refractory large B-cell lymphoma after two or more lines of therapy, and adults with relapsed/refractory follicular lymphoma after two or more lines.
The pediatric B-ALL distinction is the clearest. For children and young adults with relapsed/refractory B-ALL, Kymriah is not just “another CAR T option”—it is the signature FDA-approved CAR T in that setting. In the ELIANA trial updates cited by the National Cancer Institute, about 82% of children and young adults entered remission after Kymriah.
Kymriah also targets CD19, like Yescarta, but it uses a 4-1BB co-stimulatory domain rather than CD28. In patient terms, 4-1BB signaling is generally associated with longer persistence and a more memory-like T-cell profile, while CD28 tends to create faster effector expansion. This does not make one universally “better.” It makes them biologically different.
For adult DLBCL, the 5-year JULIET analysis reported an estimated 32% overall survival at 60 months for all infused patients and 56% among those who achieved complete or partial response. This is meaningful long-term survival in a difficult relapsed/refractory population, but it should not be directly ranked against Yescarta because the trials enrolled different patients at different times.
Carvykti: The Myeloma Game-Changer
Carvykti is the brand name for ciltacabtagene autoleucel, or cilta-cel. Unlike Yescarta and Kymriah, it does not target CD19. It targets BCMA, a protein found on myeloma plasma cells. The FDA lists Carvykti for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
This is why Carvykti is not a lymphoma treatment. It is built for multiple myeloma biology.
Carvykti is generating extraordinary attention because of long-term CARTITUDE-1 data. In the 2025 ASCO update, about 33% of heavily pretreated relapsed/refractory myeloma patients remained alive and progression-free for at least five years after a single cilta-cel infusion, without maintenance or additional anti-myeloma therapy.
That matters because multiple myeloma has historically been managed as a chronic, relapsing disease rather than cured. Oncologists are careful with the word “cure,” but long treatment-free remissions have led some experts to discuss “functional cure potential” in a subset of patients. Fred Hutch also reported expert recommendations emphasizing that patients with lymphoma, myeloma, or certain leukemias should seek CAR T expertise at relapse, not wait until they become too sick for cellular therapy.
Carvykti is also the most expensive of the three at the drug-acquisition level, with a US launch list price around $465,000 before hospital and toxicity-management costs.
Head-to-Head Comparison: The Table Every Patient Needs
Feature | Yescarta | Kymriah | Carvykti |
Generic name | Axicabtagene ciloleucel | Tisagenlecleucel | Ciltacabtagene autoleucel |
Target | CD19 | CD19 | BCMA |
Main cancer type | Adult LBCL, DLBCL-related subtypes, follicular lymphoma | Pediatric/young-adult B-ALL; adult LBCL; follicular lymphoma | Multiple myeloma |
Co-stimulatory domain | CD28 | 4-1BB | 4-1BB-based design |
Landmark long-term data | ZUMA-1: ~42.6% 5-year OS in refractory LBCL | JULIET: ~32% 5-year OS in adult r/r LBCL | CARTITUDE-1: ~33% alive and progression-free at ≥5 years |
US drug list price | Historically around $373,000+ | Historically ~$373,000–$475,000 by indication | ~$465,000 |
US total cost of care | Often $500K+ | Often $500K+ | Often $600K+ |
Key differentiator | Strong adult lymphoma data | Only pediatric/young-adult B-ALL option among these three | Strongest myeloma durability data |
If I have myeloma? | No | No | Yes |
If I have lymphoma? | Yes, if eligible | Yes, if eligible | No |
No randomized head-to-head trial has definitively proven that Yescarta is “better” than Kymriah or vice versa for every adult lymphoma patient. Real-world analyses suggest differences in toxicity and response patterns, but product choice should be individualized and heavily influenced by your diagnosis, disease speed, comorbidities, and the center’s experience.
What They All Have in Common: Side Effects and What to Expect
All three therapies can produce powerful responses, but none is a simple infusion with no risk.
Cytokine release syndrome, or CRS, is the most common early complication. It can feel like a severe inflammatory storm: fever, chills, low blood pressure, low oxygen, and sometimes ICU-level monitoring. Most CRS is manageable, but severe CRS can be dangerous and is one reason CAR T must be given by trained centers.
ICANS, or immune effector cell-associated neurotoxicity syndrome, can cause confusion, difficulty speaking, tremor, seizures, or decreased alertness. It usually resolves, but patients and caregivers need to know the warning signs.
Manufacturing failure is less discussed but very real. A 2025 multicenter analysis of large B-cell lymphoma patients reported manufacturing failure in 3.87% of approved patients, and the paper notes that manufacturing failure has been reported in roughly 1%–13% of cases in the literature.
Secondary malignancy risk also deserves a balanced explanation. In 2024, the FDA required boxed warnings for T-cell malignancies after BCMA- and CD19-directed autologous CAR T therapies, while continuing to recognize that these products have major benefits in approved indications. The practical answer for most relapsed/refractory patients is not “avoid CAR T,” but “discuss lifetime monitoring and risk-benefit carefully with your oncologist.”
The Waiting Problem: Why Manufacturing Time Can Be a Survival Issue
CAR T is not stocked on a shelf. For autologous products, your cells must be collected and manufactured into your personal therapy. In the US, the vein-to-vein process commonly takes several weeks, and patients with aggressive disease may need bridging therapy while waiting. Bridging therapy can help control cancer, but it also adds toxicity, clinic visits, and cost.
This waiting period matters. Some patients who start the process never reach infusion because their disease progresses, they become medically unstable, or manufacturing fails. That is why early referral is so important. Expert recommendations published in 2025 emphasize referral as soon as disease is considered relapsed or refractory, ideally before the next line of therapy begins.
For patients who cannot afford a 4–6 week window—or a $600,000–$1,000,000 bill—the manufacturing timeline is where international CAR T options start to look very different.
Beyond the FDA: Why International Patients Are Choosing China
US CAR T products are excellent. The evidence is real. The problem is access.
A 2024 claims-based study found median total peri-CAR T costs of $608,100, with 8.5% of patients exceeding $1 million. The median product cost alone was about $402,500, before many surrounding medical costs.
China has become one of the most active CAR T markets because it combines domestic CAR T manufacturing, commercial products, and a large clinical trial ecosystem. China has approved multiple domestic CAR T therapies, including Fucaso for relapsed/refractory multiple myeloma and relma-cel/Carteyva for large B-cell lymphoma indications.
ChinaCureLink’s 2026 cost guide estimates commercial CAR T in China at roughly $120,000–$220,000 total, with some Investigator-Initiated Trial pathways costing substantially less for qualifying patients. These are not guaranteed prices; they depend on diagnosis, protocol, hospital, length of stay, and complications. But for international patients without US insurance, the difference can be decisive. See: /cost/car-t-therapy-cost-china-2026/
China is also where many next-generation CAR T trials are being tested, especially for cancers that FDA-approved CAR T products do not yet treat. For example, Chongqing Precision Biotech is listed as a sponsor/collaborator in CD70-targeted CAR T studies for CD70-positive advanced or metastatic solid tumors, including ovarian, cervical, renal cell carcinoma, and other solid tumors.
Important: Yescarta, Kymriah, and Carvykti treat blood cancers. If you have a solid tumor such as lung, breast, colorectal, ovarian, or gastric cancer, there is currently no FDA-approved CAR T product for your cancer type. Clinical trials are where this field is moving next.
How ChinaCureLink Helps International Patients Access CAR T in China
ChinaCureLink, under the Medebound HEALTH network, coordinates the process for international patients who need advanced oncology options in China. Published ChinaCureLink materials describe Medebound HEALTH as a New York-founded medical navigation company with more than 10 years of experience, over 3,000 patients served, and a 4.6 Trustpilot rating.
The process is designed to start before you travel:
Submit medical records securely for review.
Receive an eligibility assessment for commercial CAR T or trial pathways.
Compare cost scenarios, including commercial treatment versus IIT options.
If eligible, receive a visa, hospital, travel, translation, and admission coordination.
Undergo treatment at a partner hospital with coordinator support.
Transition to post-treatment monitoring and home-country follow-up.
Primary CTA: Get a free CAR T eligibility review from a ChinaCureLink coordinator → Secondary CTA: Download the CAR T Patient Preparation Guide.
Risks and Limitations You Should Know Before Deciding Anything
This article does not replace your oncologist. CAR T eligibility depends on your pathology report, prior treatment history, organ function, infection status, performance status, disease speed, and whether your cancer expresses the right target.
Cross-trial comparisons are imperfect. Yescarta, Kymriah, and Carvykti were studied in different diseases, populations, and treatment eras. A table can help you understand the landscape, but it cannot rank products as if they were tested head-to-head.
Not all hospitals are equal, in the US or China. Accreditation, physician experience, ICU support, infection control, cell-processing quality, and international patient coordination matter.
Travel risk is real. Patients with active cancer, low blood counts, recent chemotherapy, infection risk, or rapidly progressing disease should not travel without physician clearance.
IIT trial access is not guaranteed. Lower-cost clinical trial pathways have strict criteria, and many patients will not qualify.
Frequently Asked Questions
How ChinaCureLink Can Help You Plan a Medical Trip to China
For many patients, the hardest part of CAR T therapy is not only choosing the right treatment—it is figuring out where and how to access it. International medical travel can feel overwhelming when you are already dealing with cancer, treatment delays, financial pressure, and uncertainty about eligibility.
That is where ChinaCureLink.com can help.
ChinaCureLink supports international patients who are considering advanced cancer treatment in China, including CAR T therapy, clinical trial pathways, and hospital-based oncology programs. Instead of contacting hospitals one by one, patients can work with a coordinator who helps organize the process from the first record review to post-treatment follow-up.
The service begins with a free CAR T eligibility review. Patients or caregivers submit medical records, including pathology reports, imaging results, treatment history, blood work, and recent oncology notes. These records are reviewed to help determine whether the patient may be a candidate for commercial CAR T therapy, an Investigator-Initiated Trial, or another advanced treatment option available through partner hospitals in China.
If the patient appears eligible, ChinaCureLink helps with hospital matching, cost estimates, appointment coordination, visa guidance, translation support, travel planning, and admission preparation. For patients traveling from countries where CAR T is unavailable, delayed, or financially out of reach, this coordination can reduce confusion and help families make a more informed decision.
ChinaCureLink does not replace your oncologist. Instead, it acts as a medical travel and treatment coordination partner, helping you understand whether China-based CAR T therapy is realistic for your diagnosis, budget, timeline, and medical condition.
For patients who are facing long wait times, high treatment costs, or limited access to CAR T in their home country, ChinaCureLink may provide a practical pathway to explore treatment in China safely and with professional guidance.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Conclusion
Yescarta and Kymriah are not interchangeable, even though both target CD19. Carvykti is not a lymphoma treatment; it is a BCMA-directed therapy for multiple myeloma. The right CAR T product is determined by your diagnosis, prior treatment history, target expression, disease urgency, and treatment center—not brand preference.
All three represent real advances in oncology. They also come with real risks, long logistics, and US costs that put them out of reach for many families. The CAR T landscape is not static. Faster, broader, and more accessible products are being built now, and a major part of that innovation is happening in China.
About ChinaCurelink
ChinaCurelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCurelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
Comments